Retrophin (RTRX) Upgraded to “Hold” by ValuEngine
ValuEngine upgraded shares of Retrophin (NASDAQ:RTRX) from a sell rating to a hold rating in a report published on Wednesday morning.
Several other equities analysts have also commented on the company. Zacks Investment Research upgraded Retrophin from a strong sell rating to a hold rating in a research note on Thursday, January 4th. BidaskClub lowered Retrophin from a buy rating to a hold rating in a research note on Saturday, December 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $44.00.
Retrophin (NASDAQ:RTRX) opened at $25.85 on Wednesday. The company has a current ratio of 3.80, a quick ratio of 3.74 and a debt-to-equity ratio of 0.15. Retrophin has a 52 week low of $15.55 and a 52 week high of $26.44.
COPYRIGHT VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/03/11/retrophin-rtrx-upgraded-to-hold-by-valuengine.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.